Tunitas Therapeutics, which is working on treatments for allergic diseases such as asthma, has closed a series A round co-led by WuXi PharmaTech.

US-based biopharmaceutical company Tunitas Therapeutics, closed a $10m series A round on Wednesday co-led by WuXi Ventures, the strategic investment arm of pharmaceutical company WuXi PharmaTech.

The round was co-led with healthcare-focused private equity group Ally Bridge, and also included investment bank RA Capital Advisors.

Tunitas is developing targeted protein therapeutics to treat serious allergic diseases like asthma and food allergies. The funding is expected to take its lead product candidate, an asthma treatment called epsi-gam, through initial Phase 1…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?